Center for Chemistry and Biomedicine, Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria.
Center for Chemistry and Biomedicine, Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria.
Eur J Pharm Biopharm. 2022 Jul;176:32-42. doi: 10.1016/j.ejpb.2022.05.003. Epub 2022 May 16.
The digestion behaviour of lipid-based nanocarriers (LNC) has a great impact on their oral drug delivery properties. In this study, various excipients including surfactants, glycerides and waxes, as well as various drug-delivery systems, namely self-emulsifying drug delivery systems (SEDDS), solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were examined via the pH-stat lipolysis model. Lipolysis experiments with lipase and pancreatin revealed the highest release of fatty acids for medium chain glycerides, followed by long chain glycerides and surfactants. Waxes appeared to be poor substrates with a maximum digestion of up to 10% within 60 min. Within the group of surfactants, the enzymatic cleavage decreased in the following order: glycerol monostearate > polyoxyethylene (20) sorbitan monostearate > PEG-35 castor oil > sorbitan monostearate. After digestion experiments of the excipients, SEDDS, SLN and NLC with sizes between 30 and 300 nm were prepared. The size of almost all formulations was increasing during lipolysis and levelled off after approximately 15 min except for the SLN and NLC consisting of cetyl palmitate. SEDDS exceeded 6000 nm after some minutes and were almost completely hydrolysed by pancreatin. No significant difference was observed between comparable SLN and NLC but surfactant choice and selection of the lipid component had an impact on digestion. SLN and NLC with cetyl palmitate were only digested by 5% whereas particles with glyceryl distearate were decomposed by 40-80% within 60 min. Additionally, the digestion of the same SLN or NLC, only differing in the surfactant, was higher for SLN/NLC containing polyoxyethylene (20) sorbitan monostearate than PEG-35 castor oil. This observation might be explained by the higher PEG content of PEG-35 castor oil causing a more pronounced steric hindrance for the access of lipase. Generally, digestion experiments performed with pancreatin resulted in a higher digestion compared to lipase. According to these results, the digestion behaviour of LNC depends on both, the type of nanocarrier and on the excipients used for them.
基于脂质的纳米载体(LNC)的消化行为对其口服药物传递性能有很大影响。在这项研究中,通过 pH -stat 脂肪酶水解模型研究了各种辅料,包括表面活性剂、甘油酯和蜡,以及各种药物传递系统,即自乳化药物传递系统(SEDDS)、固体脂质纳米粒(SLN)和纳米结构脂质载体(NLC)。用脂肪酶和胰酶进行的脂肪水解实验表明,中链甘油酯释放的脂肪酸最多,其次是长链甘油酯和表面活性剂。蜡似乎是较差的底物,在 60 分钟内最多消化 10%。在表面活性剂组中,酶切按以下顺序降低:甘油单硬脂酸酯>聚氧乙烯(20)山梨醇单硬脂酸酯>PEG-35 蓖麻油>山梨醇单硬脂酸酯。在消化实验后,制备了大小在 30 至 300nm 之间的 SEDDS、SLN 和 NLC。在脂肪水解过程中,几乎所有制剂的粒径都在增加,大约 15 分钟后趋于稳定,除了由十六烷酸棕榈酯组成的 SLN 和 NLC 外。SEDDS 在几分钟后超过 6000nm,并被胰酶几乎完全水解。在可比的 SLN 和 NLC 之间没有观察到显著差异,但表面活性剂的选择和脂质成分的选择对消化有影响。SEDDS 在几分钟内完全水解,而含有甘油二硬脂酸酯的 SLN 和 NLC 在 60 分钟内被分解 40-80%。此外,对于含有聚氧乙烯(20)山梨醇单硬脂酸酯的 SLN/NLC,其消化率高于含有 PEG-35 蓖麻油的 SLN/NLC,而对于相同的 SLN 或 NLC,仅表面活性剂不同。这种观察结果可以解释为 PEG-35 蓖麻油的较高 PEG 含量导致脂肪酶的进入受到更明显的空间位阻。一般来说,用胰酶进行的消化实验比用脂肪酶进行的消化实验产生更高的消化率。根据这些结果,LNC 的消化行为取决于纳米载体的类型和用于它们的赋形剂。